SB-01 peptidefor sale The SB-01 peptide, also known by its investigational name Vicatertide, is a synthetic seven-amino acid peptide designed to target and modulate the activity of Transforming Growth Factor Beta (TGF-β). This cytokine plays a significant role in various biological processes, including inflammation and tissue repair. Research has focused on SB-01's potential application in treating chronic low back pain, particularly that associated with degenerative disc disease (DDD). While clinical trials have explored its efficacy, understanding its mechanism of action, development status, and observed outcomes is crucial for evaluating its therapeutic promise.Spine Biopharma Study
SB-01 functions as a TGF-β inhibitor, meaning it binds to and antagonizes the activity of this pleiotropic cytokine.MBP-B (84-102) DRB1*15:01is a short part of the myelin basic peptide. Myelin basic protein is one of the major protein found in myelin. TGF-β is implicated in the progression of DDD by promoting fibrotic changes and inflammation within the intervertebral discs. By down-regulating TGF-β signaling, SB-01 aims to reduce these pathological processes, thereby alleviating pain and potentially slowing disc degeneration. The peptide is administered via injection directly into the spinal disc, a targeted approach designed to deliver the therapeutic agent to the site of disease.
Developed by Spine BioPharma, SB-01 has undergone significant clinical investigation, including Phase III trials. The Spine BioPharma's Phase III MODEL trial assessed the safety and effectiveness of SB-01 for Injection in adult patients experiencing chronic low back pain and related disability due to DDD. While the trial aimed to confirm the safety and effectiveness of SB-01 for Injection, topline results released in August 2025 indicated that the study failed to achieve its primary endpointSpine BioPharma Completes Enrollment in Phase 3 Trial of ....
Despite missing the primary goal, there have been reports suggesting that SB-01 demonstrated durable clinical improvements and consistent results in the Phase III MODEL trial.Emerging Use of BPC-157 in Orthopaedic Sports Medicine - PMC Further analysis of the trial data is ongoing to fully understand the implications of these findings and the potential for SB-01 in managing DDD-related pain. The development of SB-01 also involved collaborations, such as the agreement with Ensol BioSciences to expand its development.The purpose of the study is toconfirm the safety and effectiveness of SB-01 For Injectionin adult patients with chronic low back pain and related disability
* Composition: SB-01 is a synthetic peptide composed of seven amino acids.2024年9月25日—SB-01 is claimed to be the first intradiscal pharmacologic treatmentto enter Phase III trials for CLBP management and associated functional ...
* Mechanism: It acts as a TGF-β inhibitor, binding to and antagonizing TGF-β activitySB-01 is a 7-amino acid peptidethat binds to and antagonizes TGFβ1 activity. TGFβ1 is an inflammatory cytokine which is often highly expressed in the ....
* Target Condition: Primarily investigated for chronic low back pain associated with Degenerative Disc Disease (DDD)2024年9月24日—SB-01 is a 7-amino acid synthetic peptidethat binds to and antagonizes TGF-Beta activity. TGF-Beta is a pleiotropic cytokine expressed by ....
* Administration: Administered via injection into the spinal disc.Spine BioPharma, Inc. Announces Completion of ...
* Investigational Name: Vicatertide.Introducing a synthetic 7-amino acid peptide
* Developer: Spine BioPharma.2025年8月1日—SB-01 is a 7-amino acid synthetic peptidethat binds to and antagonizes TGF-Beta activity. TGF-Beta is a pleiotropic cytokine expressed by ...
While SB-01 is a specific research peptide, the broader field of peptide therapeutics continues to evolve. Other peptides, such as BPC-157, have also been explored for orthopedic and sports medicine applications, though their mechanisms and research focus differ from SB-01. It is important to distinguish SB-01 from other peptide research, such as SBP1, which involves fragments of ACE2, or MBP-B MHC II, related to myelin basic protein.
The outcome of the Phase III MODEL trial presents a complex picture for the future of SB-01. While it did not meet its primary objective, the reported durable clinical improvements warrant further investigation and discussion within the scientific and medical communities. The journey of SB-01 highlights the challenges and complexities of developing novel treatments for conditions like DDD. Continued research and detailed analysis of the trial data will be essential in determining whether SB-01, or related TGF-β modulating peptides, can ultimately offer a viable therapeutic option for patients suffering from chronic low back pain.Spine BioPharma Completes Enrollment in Phase 3 Trial of ... The peptide's status as a potential first-in-class intradiscal pharmacologic treatment for DDD underscores the ongoing need for innovative approaches in pain management.
Join the newsletter to receive news, updates, new products and freebies in your inbox.